Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis

Bone

Volumn 50, Issue 1, 2012, Pages 161-164

  Krege, J H ^a   Wan, X ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Clinical Trial; Fracture; Nonvertebral; Osteoporosis; Teriparatide

Indexed keywords

CALCIUM; PARATHYROID HORMONE[1-34]; PLACEBO; VITAMIN D;

ANKLE FRACTURE; ARTICLE; BONE RADIOGRAPHY; CLAVICLE FRACTURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SELF ADMINISTRATION; EUROPEAN UNION; FACE FRACTURE; FEMALE; FINGER FRACTURE; FOLLOW UP; FOOT FRACTURE; FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; MAJOR CLINICAL STUDY; METACARPAL BONE FRACTURE; NONVERTEBRA FRACTURE; PELVIS FRACTURE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; RADIUS FRACTURE; RANDOMIZED CONTROLLED TRIAL; RIB FRACTURE; RISK REDUCTION; SKULL FRACTURE; TOE FRACTURE; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; WRIST FRACTURE;

BONE DENSITY CONSERVATION AGENTS; FEMALE; FRACTURES, BONE; HUMANS; KAPLAN-MEIER ESTIMATE; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBOS; RISK FACTORS; TERIPARATIDE;

EID: 80355132768     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.10.018     Document Type: Article

References (17)

1. Jiang Y., Zhao J.J., Mitlak B.H., Wang O., Genant H.K., Eriksen E.F. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003, 18:1932-1941.
2. Chen P., Satterwhite J.H., Licata A.A., Lewiecki E.M., Sipos A.A., Misurski D.M., et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005, 20:962-970.
3. Keaveny T.M., Donley D.W., Hoffmann P.F., Mitlak B.H., Glass E.V., San Martin J.A. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 2007, 22:149-157.
4. Graeff C., Chevalier Y., Charlebois M., Varga P., Pahr D., Nickelsen T.N., et al. Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. J Bone Miner Res 2009, 24:1672-1680.
5. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
6. Prevrhal S., Krege J.H., Chen P., Genant H., Black D.M. Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. Curr Med Res Opin 2009, 25:921-928.
7. Division of Metabolic and Endocrine Drug Products. Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Food and Drug Administration. 1994. Available at: Accessed 26 January 2011. https://www.fda.gov.
8. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1344-1352.
9. EMA guideline on the evaluation of medicinal products in the treatment of primary osteoporosis, 2006. Doc. Ref. CMP/EWP/552/95/ Rev. 2. Available at Accessed 26 January 2011. http://www.ema.europa.eu.
10. Chesnut C.H., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19:1241-1249.
11. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11:83-91.
12. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077-2082.
13. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., Cosman F., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New Engl J Med 2007, 356:1809-1822.
14. European Medicines Agency. Forsteo label. Available at: Accessed: 26 January 2011. http://www.emea.europoa.eu.
15. US Department of Health and Human Services Bone health and osteoporosis: a report of the surgeon general. Office of the Surgeon General. Public Health Service 2004, Rockville, MD.
16. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation. 2010. Available at: Accessed: 3 March 2011. http://www.nof.org.
17. Lindsay R., Miller P., Pohl G., Glass E.V., Chen P., Krege J.H. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos Int 2009, 20:943-948.